The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension - A cohort study

Copyright © 2018 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 199(2019) vom: 10. Feb., Seite 57-61
1. Verfasser: Tiosano, Shmuel (VerfasserIn)
Weitere Verfasser: Versini, Mathilde, Dar Antaki, Lior, Spitzer, Liron, Yavne, Yarden, Watad, Abdulla, Gendelman, Omer, Comaneshter, Doron, Cohen, Arnon D, Amital, Howard
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Cohort Prognosis Pulmonary hypertension Sarcoidosis Survival
LEADER 01000naa a22002652 4500
001 NLM291739059
003 DE-627
005 20231225071532.0
007 cr uuu---uuuuu
008 231225s2019 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2018.12.012  |2 doi 
028 5 2 |a pubmed24n0972.xml 
035 |a (DE-627)NLM291739059 
035 |a (NLM)30543925 
035 |a (PII)S1521-6616(18)30722-8 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Tiosano, Shmuel  |e verfasserin  |4 aut 
245 1 4 |a The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension - A cohort study 
264 1 |c 2019 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 02.12.2019 
500 |a Date Revised 02.12.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2018 Elsevier Inc. All rights reserved. 
520 |a BACKGROUND: Sarcoidosis is a multisystem, chronic, progressive, granulomatous disease. Sarcoidosis-associated pulmonary hypertension is a well described, but not common, complication of sarcoidosis. In small scale studies, it has been previously described as manifestation of advanced disease and was found to be associated increased morbidity and mortality. This study sought to assess the long-term prognostic significance of sarcoidosis-associated pulmonary hypertension (SAPH) by using data obtained from a large population-based registry which contains longitudinal follow-up data 
520 |a METHODS: Utilizing the records of the largest healthcare provider in Israel, we extracted a cohort consisting of sarcoidosis patients and age-and-sex matched controls. Dates of sarcoidosis registration, pulmonary hypertension and death, as well as anthropometric information and medical comorbidities, were extracted from the database. A multivariate logistic regression model was used to find variables associated with pulmonary hypertension. Cox proportional hazards method and log-rank test were used for survival analysis 
520 |a RESULTS: The cohort included 3993 sarcoidosis patients and 19,856 controls. Pulmonary hypertension was observed among 269 sarcoidosis patients (6.74%) vs. 400 controls (2.01%). Sarcoidosis was found as independently associated with pulmonary hypertension (OR 3.17). After a mean follow-up of 7.49 years (median 7.24, maximum 17.88 years), 710 (17.8%) of the sarcoidosis patients and 2121 (10.7%) of the controls had died. Both sarcoidosis and pulmonary hypertension were found to be significantly associated with an increased risk of all-cause mortality (HR 1.82 and HR 2.31, respectively) 
520 |a CONCLUSIONS: SAPH is associated with a poor prognosis. Proper screening methods may assess whether early identification and treatment improve life expectancy 
650 4 |a Journal Article 
650 4 |a Cohort 
650 4 |a Prognosis 
650 4 |a Pulmonary hypertension 
650 4 |a Sarcoidosis 
650 4 |a Survival 
700 1 |a Versini, Mathilde  |e verfasserin  |4 aut 
700 1 |a Dar Antaki, Lior  |e verfasserin  |4 aut 
700 1 |a Spitzer, Liron  |e verfasserin  |4 aut 
700 1 |a Yavne, Yarden  |e verfasserin  |4 aut 
700 1 |a Watad, Abdulla  |e verfasserin  |4 aut 
700 1 |a Gendelman, Omer  |e verfasserin  |4 aut 
700 1 |a Comaneshter, Doron  |e verfasserin  |4 aut 
700 1 |a Cohen, Arnon D  |e verfasserin  |4 aut 
700 1 |a Amital, Howard  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 199(2019) vom: 10. Feb., Seite 57-61  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:199  |g year:2019  |g day:10  |g month:02  |g pages:57-61 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2018.12.012  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 199  |j 2019  |b 10  |c 02  |h 57-61